Blueprint Medicines (BPMC) Financials

$82.53 +1.69 (+2.09%)

Closing price 04/14/2025 04:00 PM Eastern

Extended Trading

$82.60 +0.07 (+0.08%)

As of 08:03 AM Eastern

Annual Income Statements for Blueprint Medicines

This table shows Blueprint Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-56	-72	-148	-237	-348	314	-644	-558	-507	-67
Consolidated Net Income / (Loss)	-53	-72	-148	-237	-348	314	-644	-558	-507	-67
Net Income / (Loss) Continuing Operations	-53	-72	-148	-237	-348	314	-644	-558	-507	-66
Total Pre-Tax Income	-53	-72	-148	-237	-348	315	-641	-552	-506	-66
Total Operating Income	-52	-73	-151	-247	-361	309	-642	-538	-486	-212
Total Gross Profit	11	28	21	45	67	793	162	186	241	489
Total Revenue	11	28	21	45	67	794	180	204	249	509
Operating Revenue	11	28	21	45	67	794	180	204	249	509
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.43	18	18	8.54	20
Operating Cost of Revenue	-	-	-	0.00	0.00	0.43	18	18	8.54	20
Total Operating Expenses	63	100	173	292	428	485	822	724	727	701
Selling, General & Admin Expense	14	19	28	48	96	158	195	237	295	359
Research & Development Expense	49	81	145	244	331	327	601	477	428	341
Other Operating Expenses / (Income)	-	-	-	-	0.00	0.00	7.80	8.95	4.26	0.00
Total Other Income / (Expense), net	-1.13	0.08	3.13	10	14	6.23	0.90	-15	-20	146
Interest Expense	0.70	0.47	-3.20	-11	-14	-6.60	-2.39	0.00	0.00	-174
Interest & Investment Income	-	-	-	-	-	-	-	-17	-19	-28
Income Tax Expense	-	-	-	0.00	0.00	1.06	3.00	5.24	0.97	1.23
Other Gains / (Losses), net	-	-	-	-	-	-	-	-	-	0.66
Basic Earnings per Share	-	($2.64)	($3.92)	($5.39)	($7.27)	$5.76	($11.01)	($9.35)	($8.37)	($1.07)
Weighted Average Basic Shares Outstanding	18.24M	27.49M	37.79M	43.87M	47.83M	54.53M	58.52M	59.64M	60.56M	62.86M
Diluted Earnings per Share	-	($2.64)	($3.92)	($5.39)	($7.27)	$5.59	($11.01)	($9.35)	($8.37)	($1.07)
Weighted Average Diluted Shares Outstanding	18.24M	27.49M	37.79M	43.87M	47.83M	56.17M	58.52M	59.64M	60.56M	62.86M
Weighted Average Basic & Diluted Shares Outstanding	18.24M	27.49M	37.79M	43.87M	47.83M	54.53M	59.20K	59.98M	61.23M	63.91M

This table shows Blueprint Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-133	-159	-130	-132	-132	-113	89	-50	-53	-53
Consolidated Net Income / (Loss)	-133	-159	-130	-133	-134	-111	89	-50	-56	-50
Net Income / (Loss) Continuing Operations	-133	-159	-130	-133	-134	-111	89	-50	-56	-49
Total Pre-Tax Income	-132	-158	-129	-133	-134	-111	89	-50	-56	-49
Total Operating Income	-124	-150	-124	-128	-129	-105	-79	-43	-49	-41
Total Gross Profit	63	34	60	55	54	72	93	131	126	139
Total Revenue	66	39	63	58	57	72	96	138	128	146
Operating Revenue	66	39	63	58	57	72	96	138	128	146
Total Cost of Revenue	3.00	4.85	3.18	2.32	2.78	0.26	3.19	7.59	1.93	7.45
Operating Cost of Revenue	3.00	4.85	3.18	2.32	2.78	0.26	3.19	7.59	1.93	7.45
Total Operating Expenses	187	184	184	183	183	177	172	174	175	180
Selling, General & Admin Expense	58	64	71	72	71	82	84	89	90	96
Research & Development Expense	128	118	112	110	110	95	88	84	85	84
Total Other Income / (Expense), net	-8.00	-7.81	-4.83	-4.62	-4.54	-5.75	168	-6.85	-7.03	-8.08
Interest Expense	8.40	-7.53	5.82	0.00	0.00	-5.82	-168	-0.02	0.00	-5.90
Income Tax Expense	0.89	1.04	0.52	0.19	0.20	0.06	0.18	0.10	0.27	0.67
Basic Earnings per Share	($2.23)	($2.65)	($2.15)	($2.19)	($2.20)	($1.83)	$1.45	($0.80)	($0.89)	($0.83)
Weighted Average Basic Shares Outstanding	59.76M	59.64M	60.13M	60.52M	60.69M	60.56M	61.58M	62.85M	63.38M	62.86M
Diluted Earnings per Share	($2.23)	($2.65)	($2.15)	($2.19)	($2.20)	($1.83)	$1.40	($0.80)	($0.89)	($0.78)
Weighted Average Diluted Shares Outstanding	59.76M	59.64M	60.13M	60.52M	60.69M	60.56M	63.80M	62.85M	63.38M	62.86M
Weighted Average Basic & Diluted Shares Outstanding	59.83M	59.98M	60.47M	60.66M	60.79M	61.23M	62.62M	63.35M	63.53M	63.91M

This table details how cash moves in and out of Blueprint Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	115	-111	352	-332	46	571	-474	-90	-44	33
Net Cash From Operating Activities	-32	-25	-120	-175	-278	387	-299	-502	-437	-193
Net Cash From Continuing Operating Activities	-32	-25	-120	-175	-278	387	-299	-502	-437	-193
Net Income / (Loss) Continuing Operations	-53	-72	-148	-237	-348	314	-644	-558	-507	-67
Consolidated Net Income / (Loss)	-53	-72	-148	-237	-348	314	-644	-558	-507	-67
Depreciation Expense	0.95	1.58	1.58	4.25	5.26	6.56	6.48	12	12	16
Amortization Expense	0.11	-	-	-	-	-	1.36	-0.98	-17	-22
Non-Cash Adjustments To Reconcile Net Income	5.63	6.44	16	26	32	86	364	92	129	-54
Changes in Operating Assets and Liabilities, net	14	40	11	31	32	-20	-27	-47	-53	-66
Net Cash From Investing Activities	-6.08	-219	-72	-161	-16	-434	-226	-150	274	-48
Net Cash From Continuing Investing Activities	-6.08	-219	-72	-161	-16	-434	-226	-150	274	-48
Purchase of Property, Plant & Equipment	-4.88	-2.35	-16	-13	-14	-3.16	-3.09	-8.92	-16	-4.63
Purchase of Investments	0.00	-264	-361	-801	-738	-969	-655	-490	-766	-966
Sale and/or Maturity of Investments	0.00	48	304	653	736	538	691	349	1,056	924
Other Investing Activities, net	-1.20	-	-	-	-	0.00	0.00	-0.29	0.00	0.00
Net Cash From Financing Activities	153	133	544	4.45	341	618	51	562	119	273
Net Cash From Continuing Financing Activities	153	133	544	4.45	341	618	51	562	119	273
Repayment of Debt	-1.81	-3.33	-2.58	-1.97	-0.12	0.00	0.00	554	98	146
Issuance of Common Equity	157	136	547	0.00	327	582	-	0.00	0.00	49
Other Financing Activities, net	-	-	-	6.43	13	35	51	8.20	21	78
Cash Interest Paid	0.45	0.32	0.15	0.27	-	0.00	0.00	9.81	38	80
Cash Income Taxes Paid	-	-	0.04	0.12	0.19	0.78	0.69	6.51	-0.05	1.10

This table details how cash moves in and out of Blueprint Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	118	-172	50	-93	-16	15	43	-58	35	14
Net Cash From Operating Activities	-130	-121	-123	-130	-104	-79	-102	-48	-14	-29
Net Cash From Continuing Operating Activities	-130	-121	-123	-130	-104	-79	-102	-48	-14	-29
Net Income / (Loss) Continuing Operations	-133	-159	-130	-133	-134	-111	89	-50	-56	-50
Consolidated Net Income / (Loss)	-133	-159	-130	-133	-134	-111	89	-50	-56	-50
Depreciation Expense	1.62	7.02	3.68	3.58	2.87	1.53	4.81	3.62	3.86	4.00
Amortization Expense	-	-1.83	-2.38	-3.71	-5.44	-5.94	-5.19	-5.65	-6.33	-5.29
Non-Cash Adjustments To Reconcile Net Income	6.79	23	30	30	29	40	-146	31	30	31
Changes in Operating Assets and Liabilities, net	-5.99	9.46	-25	-27	2.84	-3.85	-44	-27	15	-9.59
Net Cash From Investing Activities	-132	-53	173	32	-9.59	79	77	-188	30	34
Net Cash From Continuing Investing Activities	-132	-53	173	32	-9.59	79	77	-188	30	34
Purchase of Property, Plant & Equipment	-3.73	-1.48	-2.58	-2.55	-6.25	-4.67	-1.10	-2.57	-0.03	-0.93
Purchase of Investments	-219	-231	-133	-275	-241	-118	-200	-355	-201	-210
Sale and/or Maturity of Investments	91	179	308	310	238	201	278	170	231	244
Net Cash From Financing Activities	381	2.49	0.00	5.30	98	16	67	178	18	9.76
Net Cash From Continuing Financing Activities	381	2.49	0.00	5.30	98	16	67	178	18	9.76
Other Financing Activities, net	1.92	2.51	0.00	5.30	0.43	16	18	31	18	9.76
Cash Interest Paid	2.96	6.86	7.08	8.08	10	13	14	18	23	24
Cash Income Taxes Paid	3.25	2.49	0.31	0.37	0.09	-0.81	0.52	0.03	0.24	0.32

This table presents Blueprint Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	179	283	716	540	708	1,718	1,252	1,350	1,049	1,180
Total Current Assets	170	220	686	500	517	928	554	1,047	808	743
Cash & Equivalents	163	52	400	68	114	685	210	120	71	102
Short-Term Investments	0.00	162	273	426	370	187	267	825	639	513
Accounts Receivable	3.41	-	-	0.06	0.66	7.10	25	24	43	76
Inventories, net	-	-	-	-	0.00	8.58	22	30	21	14
Prepaid Expenses	4.18	2.69	12	5.56	9.82	22	18	35	33	36
Other Current Assets	-	3.58	-	0.15	23	18	12	13	0.35	1.81
Plant, Property, & Equipment, net	6.66	6.19	24	30	38	34	31	33	42	37
Total Noncurrent Assets	1.82	56	5.87	11	153	757	668	270	199	401
Long-Term Investments	0.00	54	-	0.00	64	678	558	133	57	248
Other Noncurrent Operating Assets	0.56	0.86	5.87	11	88	79	110	136	142	152
Total Liabilities & Shareholders' Equity	179	283	716	540	708	1,718	1,252	1,350	1,049	1,180
Total Liabilities	35	70	92	121	243	248	281	835	919	881
Total Current Liabilities	19	29	43	60	106	131	150	183	215	261
Short-Term Debt	3.27	2.55	1.52	-	-	-	-	17	30	44
Accounts Payable	2.46	2.21	3.74	3.30	4.79	4.37	8.33	2.73	4.71	6.79
Accrued Expenses	6.44	12	31	52	89	106	122	131	128	133
Current Deferred Revenue	5.90	11	5.37	3.60	6.16	13	12	4.67	40	64
Other Current Liabilities	0.58	0.58	1.71	1.71	6.82	7.94	8.09	28	12	13
Total Noncurrent Liabilities	16	41	49	61	137	118	132	652	704	620
Long-Term Debt	4.07	1.52	-	-	-	-	-	535	611	537
Capital Lease Obligations	3.37	2.79	15	13	-	-	-	-	82	69
Noncurrent Deferred Revenue	8.58	37	34	48	40	29	25	14	4.79	8.19
Other Noncurrent Operating Liabilities	0.25	0.15	0.13	0.19	97	89	107	103	6.21	6.79
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	144	213	624	419	464	1,470	971	515	131	299
Total Preferred & Common Equity	144	213	624	419	464	1,470	971	515	131	299
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	144	213	624	419	464	1,470	971	515	131	299
Common Stock	279	421	980	1,017	1,412	2,107	2,250	2,358	2,474	2,709
Retained Earnings	-135	-207	-356	-598	-945	-631	-1,275	-1,833	-2,340	-2,407
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.02	-0.27	-0.18	-2.54	-5.21	-4.13	-10	-3.50	-3.55

This table presents Blueprint Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,458	1,220	1,106	1,105	1,038	1,204	1,200
Total Current Assets	1,228	900	811	808	777	904	855
Cash & Equivalents	291	170	76	56	113	55	89
Short-Term Investments	846	652	647	657	535	709	645
Accounts Receivable	19	31	38	41	60	85	66
Inventories, net	35	18	17	16	31	15	13
Prepaid Expenses	34	29	33	37	38	40	42
Plant, Property, & Equipment, net	33	34	37	41	42	40	38
Total Noncurrent Assets	197	286	258	257	220	260	307
Long-Term Investments	56	139	114	114	88	105	148
Other Noncurrent Operating Assets	142	147	144	142	132	155	159
Total Liabilities & Shareholders' Equity	1,458	1,220	1,106	1,105	1,038	1,204	1,200
Total Liabilities	818	806	795	903	728	883	887
Total Current Liabilities	176	173	169	197	207	244	258
Short-Term Debt	15	17	18	30	30	48	45
Accounts Payable	4.23	11	6.98	6.96	4.93	4.86	4.72
Accrued Expenses	121	109	101	110	107	121	131
Current Deferred Revenue	4.63	25	32	38	52	57	64
Other Current Liabilities	31	11	11	12	12	13	13
Total Noncurrent Liabilities	643	633	626	705	521	640	629
Long-Term Debt	526	535	531	613	432	550	543
Capital Lease Obligations	-	90	87	84	78	75	72
Noncurrent Deferred Revenue	12	5.00	5.00	5.00	4.64	8.04	7.92
Other Noncurrent Operating Liabilities	104	3.10	3.16	3.10	5.77	5.78	6.17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	640	414	311	203	311	320	313
Total Preferred & Common Equity	640	414	311	203	311	320	313
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	640	414	311	203	311	320	313
Common Stock	2,329	2,381	2,411	2,434	2,565	2,625	2,671
Retained Earnings	-1,674	-1,963	-2,095	-2,229	-2,251	-2,301	-2,357
Accumulated Other Comprehensive Income / (Loss)	-15	-4.60	-4.22	-2.68	-3.85	-3.89	-1.07

This table displays calculated financial ratios and metrics derived from Blueprint Medicines' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	143.61%	-22.85%	107.79%	49.39%	1,093.37%	-77.31%	13.30%	22.22%	104.04%
EBITDA Growth	-30.39%	-38.08%	-112.57%	-62.25%	-46.59%	188.41%	-301.85%	17.44%	6.05%	55.74%
EBIT Growth	-30.73%	-38.32%	-110.10%	-63.36%	-46.20%	185.31%	-308.69%	16.78%	9.02%	56.48%
NOPAT Growth	-29.97%	-40.53%	-108.40%	-63.33%	-46.27%	221.64%	-246.06%	16.27%	9.53%	56.39%
Net Income Growth	-30.99%	-37.38%	-104.32%	-59.76%	-46.93%	190.28%	-305.20%	13.44%	9.06%	86.77%
EPS Growth	0.00%	0.00%	-48.48%	-37.50%	-34.88%	176.89%	-296.96%	15.08%	10.48%	87.22%
Operating Cash Flow Growth	10.52%	22.61%	-388.99%	-46.01%	-58.86%	239.21%	-177.16%	-68.18%	13.03%	55.91%
Free Cash Flow Firm Growth	-19.50%	64.10%	-1,045.73%	-17.93%	-60.63%	231.23%	-253.15%	7.87%	-2.33%	66.70%
Invested Capital Growth	-217.95%	-426.80%	32.89%	-86.76%	-34.62%	4.75%	19.75%	81.74%	840.80%	-2.80%
Revenue Q/Q Growth	68.51%	12.36%	-22.06%	-1.32%	315.39%	-2.15%	68.04%	-25.06%	15.34%	17.13%
EBITDA Q/Q Growth	-1.93%	-8.94%	-26.36%	-18.41%	5.83%	-4.98%	-56.41%	24.74%	6.29%	23.39%
EBIT Q/Q Growth	-2.15%	-8.69%	-26.01%	-18.47%	5.65%	-5.11%	-55.85%	23.90%	8.05%	23.05%
NOPAT Q/Q Growth	-2.23%	-8.93%	-23.44%	-15.45%	3.67%	-5.42%	-55.89%	23.63%	8.42%	23.16%
Net Income Q/Q Growth	-2.14%	-8.51%	-23.07%	-15.24%	3.87%	-5.80%	-56.69%	22.30%	8.60%	47.61%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	6.44%	2.57%	-62.87%	22.92%	8.92%	49.53%
Operating Cash Flow Q/Q Growth	-4.85%	-30.65%	-15.35%	-23.09%	7.54%	5.48%	3.45%	-27.16%	8.86%	20.47%
Free Cash Flow Firm Q/Q Growth	0.00%	-5.90%	-35.52%	-5.20%	4.04%	7.29%	-67.63%	18.94%	9.64%	19.30%
Invested Capital Q/Q Growth	19.66%	-2.63%	24.25%	-9.46%	-7.02%	-121.82%	-36.82%	-7.94%	-15.93%	-7.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	99.95%	90.04%	91.27%	96.58%	96.04%
EBITDA Margin	-447.51%	-253.65%	-698.89%	-545.72%	-535.49%	39.67%	-352.97%	-257.19%	-197.70%	-42.89%
Operating Margin	-453.02%	-261.33%	-705.90%	-554.86%	-543.25%	38.89%	-356.50%	-263.44%	-194.99%	-41.67%
EBIT Margin	-456.78%	-259.35%	-706.26%	-555.26%	-543.40%	38.85%	-357.32%	-262.46%	-195.37%	-41.67%
Profit (Net Income) Margin	-462.89%	-261.04%	-691.31%	-531.53%	-522.75%	39.54%	-357.67%	-273.24%	-203.30%	-13.19%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	99.66%	100.47%	100.95%	100.19%	101.86%
Interest Burden Percent	101.34%	100.65%	97.88%	95.73%	96.20%	102.14%	99.63%	103.13%	103.86%	31.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.34%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-910.61%	-174.17%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-852.21%	-237.03%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	753.47%	142.92%
Return on Equity (ROE)	-58.83%	-40.61%	-35.39%	-45.38%	-78.72%	32.45%	-52.78%	-75.07%	-157.13%	-31.26%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-507.34%	-171.34%
Operating Return on Assets (OROA)	-45.51%	-31.20%	-30.31%	-39.37%	-57.93%	25.42%	-43.32%	-41.16%	-40.62%	-19.03%
Return on Assets (ROA)	-46.12%	-31.40%	-29.67%	-37.69%	-55.73%	25.88%	-43.36%	-42.85%	-42.26%	-6.02%
Return on Common Equity (ROCE)	-21.18%	-40.61%	-35.39%	-45.38%	-78.72%	32.45%	-52.78%	-75.07%	-157.13%	-31.26%
Return on Equity Simple (ROE_SIMPLE)	-36.65%	-34.02%	-23.74%	-56.48%	-74.88%	21.35%	-66.35%	-108.32%	-388.17%	-22.46%
Net Operating Profit after Tax (NOPAT)	-36	-51	-106	-173	-253	308	-449	-376	-340	-148
NOPAT Margin	-317.11%	-182.93%	-494.13%	-388.40%	-380.27%	38.76%	-249.55%	-184.41%	-136.50%	-29.17%
Net Nonoperating Expense Percent (NNEP)	-17.33%	-10.43%	-9.19%	-11.20%	-18.42%	0.59%	-15.07%	-23.22%	-58.40%	62.85%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-35.27%	-39.88%	-15.66%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%	9.96%	8.73%	3.42%	3.96%
SG&A Expenses to Revenue	126.81%	69.20%	130.62%	107.65%	144.92%	19.87%	108.45%	116.34%	118.35%	70.61%
R&D to Revenue	426.21%	292.13%	675.29%	547.20%	498.33%	41.18%	333.76%	233.99%	171.51%	67.10%
Operating Expenses to Revenue	553.02%	361.33%	805.90%	654.86%	643.25%	61.05%	456.50%	354.71%	291.57%	137.71%
Earnings before Interest and Taxes (EBIT)	-52	-72	-151	-247	-361	308	-643	-536	-487	-212
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-51	-70	-150	-243	-356	315	-636	-525	-493	-218
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.96	3.60	4.74	5.65	8.49	4.25	6.49	5.09	42.93	18.55
Price to Tangible Book Value (P/TBV)	4.96	3.60	4.74	5.65	8.49	4.25	6.49	5.09	42.93	18.55
Price to Revenue (P/Rev)	62.62	27.60	137.98	53.22	59.26	7.87	35.00	12.85	22.48	10.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	19.91	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	5.02%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	64.37	63.40
Enterprise Value to Revenue (EV/Rev)	49.27	18.19	107.30	42.41	51.02	5.92	29.25	10.27	22.31	10.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	14.93	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	15.24	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	15.28	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	12.14	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	15.48	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.07	0.03	0.03	0.03	0.00	0.00	0.00	1.07	5.54	2.17
Long-Term Debt to Equity	0.05	0.02	0.02	0.03	0.00	0.00	0.00	1.04	5.30	2.03
Financial Leverage	-1.07	-1.17	-1.10	-1.09	-1.16	-1.08	-1.06	-1.05	-0.88	-0.60
Leverage Ratio	1.28	1.29	1.19	1.20	1.41	1.25	1.22	1.75	3.72	5.19
Compound Leverage Factor	1.29	1.30	1.17	1.15	1.36	1.28	1.21	1.81	3.86	1.61
Debt to Total Capital	6.92%	3.12%	2.52%	2.99%	0.00%	0.00%	0.00%	51.76%	84.70%	68.49%
Short-Term Debt to Total Capital	2.11%	1.16%	0.24%	0.00%	0.00%	0.00%	0.00%	1.58%	3.55%	4.63%
Long-Term Debt to Total Capital	4.81%	1.96%	2.28%	2.99%	0.00%	0.00%	0.00%	50.18%	81.15%	63.86%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	93.08%	96.88%	97.48%	97.01%	100.00%	100.00%	100.00%	48.24%	15.30%	31.51%
Debt to EBITDA	-0.21	-0.10	-0.11	-0.05	0.00	0.00	0.00	-1.05	-1.47	-2.98
Net Debt to EBITDA	2.98	3.71	4.39	1.98	0.00	0.00	0.00	1.00	0.09	0.98
Long-Term Debt to EBITDA	-0.15	-0.06	-0.10	-0.05	0.00	0.00	0.00	-1.02	-1.41	-2.77
Debt to NOPAT	-0.30	-0.14	-0.15	-0.07	0.00	0.00	0.00	-1.47	-2.12	-4.37
Net Debt to NOPAT	4.21	5.14	6.21	2.78	0.00	0.00	0.00	1.40	0.13	1.45
Long-Term Debt to NOPAT	-0.21	-0.08	-0.14	-0.07	0.00	0.00	0.00	-1.42	-2.04	-4.08
Altman Z-Score	11.33	5.64	19.04	9.74	6.95	16.20	10.84	-0.41	-0.08	1.24
Noncontrolling Interest Sharing Ratio	63.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.14	7.73	15.98	8.29	4.85	7.09	3.70	5.71	3.76	2.85
Quick Ratio	8.91	7.51	15.70	8.19	4.55	6.72	3.35	5.29	3.51	2.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-30	-11	-122	-144	-231	304	-465	-429	-438	-146
Operating Cash Flow to CapEx	-648.70%	-1,041.33%	-772.72%	-1,380.52%	-1,983.98%	12,251.82%	-9,668.27%	-5,631.54%	-2,719.75%	-4,159.52%
Free Cash Flow to Firm to Interest Expense	-42.68	-22.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-45.51	-52.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-52.53	-57.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.10	0.12	0.04	0.07	0.11	0.65	0.12	0.16	0.21	0.46
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	182.98	204.60	11.17	8.38	7.52	8.58
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	1.18	0.69	0.34	1.16
Fixed Asset Turnover	2.80	4.32	1.40	1.65	1.96	21.90	5.56	6.37	6.62	12.96
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.09	2.82	3.22	2.30	3.51
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	1.99	1.78	32.68	43.54	48.56	42.55
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	309.34	527.78	1,088.16	315.29
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	3,934.70	129.27	113.33	158.97	104.09
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	1.99	-3,932.92	212.75	457.99	977.75	253.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-9.41	-50	-33	-62	-84	-80	-64	-12	86	84
Invested Capital Turnover	-1.84	-0.94	-0.52	-0.93	-0.91	-9.73	-2.51	-5.40	6.67	5.97
Increase / (Decrease) in Invested Capital	-6.45	-40	16	-29	-22	3.97	16	52	98	-2.42
Enterprise Value (EV)	562	505	2,299	1,888	3,394	4,700	5,267	2,095	5,563	5,326
Market Capitalization	714	767	2,956	2,369	3,942	6,250	6,302	2,621	5,607	5,541
Book Value per Share	$5.31	$7.80	$15.92	$9.53	$9.44	$26.38	$16.50	$8.60	$2.15	$4.70
Tangible Book Value per Share	$5.31	$7.80	$15.92	$9.53	$9.44	$26.38	$16.50	$8.60	$2.15	$4.70
Total Capital	155	220	640	432	464	1,470	971	1,067	854	948
Total Debt	11	6.86	16	13	0.00	0.00	0.00	552	723	649
Total Long-Term Debt	7.44	4.31	15	13	0.00	0.00	0.00	535	693	605
Net Debt	-152	-261	-657	-481	-548	-1,550	-1,035	-526	-44	-215
Capital Expenditures (CapEx)	4.88	2.35	16	13	14	3.16	3.09	8.92	16	4.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.78	-20	-29	-55	-73	-75	-73	-65	-87	-90
Debt-free Net Working Capital (DFNWC)	155	194	644	439	410	797	404	880	624	526
Net Working Capital (NWC)	152	192	643	439	410	797	404	863	593	482
Net Nonoperating Expense (NNE)	17	22	42	64	95	-6.21	195	181	167	-81
Net Nonoperating Obligations (NNO)	-153	-263	-657	-481	-548	-1,550	-1,035	-526	-44	-215
Total Depreciation and Amortization (D&A)	1.06	1.58	1.58	4.25	5.26	6.56	7.84	11	-5.80	-6.17
Debt-free, Cash-free Net Working Capital to Revenue	-68.28%	-70.92%	-136.39%	-122.52%	-110.13%	-9.44%	-40.46%	-31.72%	-34.84%	-17.63%
Debt-free Net Working Capital to Revenue	1,360.02%	700.22%	3,006.31%	987.09%	616.89%	100.41%	224.49%	431.43%	250.12%	103.34%
Net Working Capital to Revenue	1,331.37%	691.03%	2,999.23%	987.09%	616.89%	100.41%	224.49%	423.17%	237.98%	94.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	($7.27)	$5.76	($11.01)	($9.35)	($8.37)	($1.07)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	54.03M	54.53M	58.52M	59.64M	60.56M	62.86M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($7.27)	$5.59	($11.01)	($9.35)	($8.37)	($1.07)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	54.03M	56.17M	58.52M	59.64M	60.56M	62.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($7.27)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	47.83M	57.96M	59.20K	59.98M	61.23M	63.91M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-51	-106	-173	-253	308	-449	-376	-340	-148
Normalized NOPAT Margin	-317.11%	-182.93%	-494.13%	-388.40%	-380.27%	38.76%	-249.55%	-184.41%	-136.50%	-29.17%
Pre Tax Income Margin	-462.89%	-261.04%	-691.31%	-531.53%	-522.75%	39.68%	-356.00%	-270.68%	-202.91%	-12.94%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-74.82	-153.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-51.94	-108.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-81.83	-158.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-58.96	-113.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.88%	-0.20%	-0.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Blueprint Medicines' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	172.77%	-63.76%	0.89%	57.52%	-14.26%	85.55%	51.87%	139.98%	126.61%	103.41%
EBITDA Growth	-5.39%	54.52%	-16.52%	17.23%	-8.19%	23.11%	35.34%	64.99%	61.55%	61.40%
EBIT Growth	-5.32%	53.12%	-15.97%	18.09%	-4.70%	28.77%	36.34%	66.53%	62.70%	61.02%
NOPAT Growth	-6.13%	52.62%	-17.39%	18.81%	-3.78%	29.83%	9.52%	66.37%	62.03%	60.80%
Net Income Growth	-13.58%	50.22%	-22.23%	16.85%	-0.41%	30.08%	168.80%	62.35%	57.91%	54.96%
EPS Growth	-11.50%	51.20%	-20.11%	18.28%	1.35%	30.94%	165.12%	63.47%	59.55%	57.38%
Operating Cash Flow Growth	-35.87%	-760.17%	7.36%	-10.33%	19.56%	34.99%	17.44%	63.16%	86.95%	62.80%
Free Cash Flow Firm Growth	-72.71%	33.72%	-110.07%	43.81%	-65.92%	-9.28%	49.02%	65.18%	89.18%	84.61%
Invested Capital Growth	76.86%	81.74%	918.61%	57.91%	1,051.14%	840.80%	21.32%	13.73%	-11.89%	-2.80%
Revenue Q/Q Growth	80.53%	-41.22%	63.19%	-9.03%	-1.74%	27.21%	33.57%	43.74%	-7.22%	14.19%
EBITDA Q/Q Growth	21.39%	-17.11%	14.85%	-5.60%	-2.75%	16.77%	28.40%	42.82%	-12.83%	16.45%
EBIT Q/Q Growth	21.10%	-19.77%	16.95%	-4.37%	-0.86%	18.52%	25.77%	45.13%	-12.41%	14.85%
NOPAT Q/Q Growth	21.16%	-20.54%	17.08%	-3.04%	-0.78%	18.51%	-6.92%	61.70%	-13.77%	15.87%
Net Income Q/Q Growth	16.62%	-19.14%	18.33%	-2.50%	-0.69%	17.05%	180.36%	-156.09%	-12.57%	11.23%
EPS Q/Q Growth	16.79%	-18.83%	18.87%	-1.86%	-0.46%	16.82%	176.50%	-157.14%	-11.25%	12.36%
Operating Cash Flow Q/Q Growth	-9.84%	6.53%	-1.28%	-6.11%	19.92%	24.46%	-28.61%	52.64%	71.63%	-115.33%
Free Cash Flow Firm Q/Q Growth	46.94%	-27.83%	-23.67%	33.02%	-56.69%	15.81%	-10.16%	54.26%	51.31%	-19.80%
Invested Capital Q/Q Growth	-115.44%	-7.94%	919.88%	15.57%	-7.00%	-15.93%	2,380.70%	8.34%	-27.95%	-7.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.45%	87.50%	94.98%	95.96%	95.08%	99.64%	96.68%	94.50%	98.49%	94.91%
EBITDA Margin	-185.31%	-369.20%	-192.64%	-223.62%	-233.84%	-153.00%	-82.02%	-32.63%	-39.68%	-29.03%
Operating Margin	-188.36%	-386.27%	-196.26%	-222.31%	-228.02%	-146.07%	-82.01%	-31.16%	-38.21%	-28.15%
EBIT Margin	-187.76%	-382.58%	-194.70%	-223.39%	-229.30%	-146.88%	-81.62%	-31.16%	-37.75%	-28.15%
Profit (Net Income) Margin	-201.83%	-409.08%	-204.72%	-230.66%	-236.38%	-154.14%	92.74%	-36.19%	-43.90%	-34.13%
Tax Burden Percent	100.67%	100.66%	100.40%	100.14%	100.15%	100.06%	99.80%	100.20%	100.49%	101.36%
Interest Burden Percent	106.78%	106.23%	104.72%	103.11%	102.94%	104.89%	-113.86%	115.90%	115.74%	119.62%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-669.46%	-388.90%	-750.19%	-682.14%	-218.20%	-66.98%	-120.15%	-117.65%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-662.43%	-379.07%	-738.62%	-669.05%	-283.58%	-56.92%	-106.50%	-101.34%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	619.51%	314.43%	658.01%	591.54%	200.78%	35.62%	66.57%	61.10%
Return on Equity (ROE)	-76.04%	-75.07%	-49.95%	-74.47%	-92.18%	-90.61%	-17.43%	-31.36%	-53.58%	-56.55%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-519.04%	-452.97%	-472.04%	-507.34%	-310.83%	-223.77%	-187.12%	-171.34%
Operating Return on Assets (OROA)	-34.83%	-60.00%	-33.71%	-43.85%	-38.68%	-30.53%	-20.39%	-9.79%	-14.23%	-12.85%
Return on Assets (ROA)	-37.44%	-64.15%	-35.44%	-45.28%	-39.87%	-32.05%	23.17%	-11.37%	-16.55%	-15.58%
Return on Common Equity (ROCE)	-76.04%	-75.07%	-49.95%	-74.47%	-92.18%	-90.61%	-17.43%	-31.36%	-53.58%	-56.55%
Return on Equity Simple (ROE_SIMPLE)	-112.06%	0.00%	-140.26%	-178.11%	-273.78%	0.00%	-92.79%	-64.17%	-40.89%	0.00%
Net Operating Profit after Tax (NOPAT)	-87	-105	-87	-90	-90	-74	-79	-30	-34	-29
NOPAT Margin	-131.85%	-270.39%	-137.38%	-155.61%	-159.61%	-102.25%	-81.84%	-21.81%	-26.74%	-19.70%
Net Nonoperating Expense Percent (NNEP)	-4.75%	-6.89%	-7.03%	-9.84%	-11.57%	-13.09%	65.38%	-10.05%	-13.65%	-16.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.83%	-	-	-	-8.62%	-	-	-	-3.04%
Cost of Revenue to Revenue	4.55%	12.50%	5.02%	4.04%	4.92%	0.36%	3.32%	5.50%	1.51%	5.09%
SG&A Expenses to Revenue	87.32%	165.08%	112.11%	124.95%	125.06%	113.29%	86.93%	64.66%	70.15%	65.90%
R&D to Revenue	193.98%	303.86%	177.09%	191.18%	194.91%	132.48%	91.75%	61.00%	66.55%	57.17%
Operating Expenses to Revenue	283.82%	473.77%	291.24%	318.27%	323.10%	245.71%	178.69%	125.66%	136.70%	123.06%
Earnings before Interest and Taxes (EBIT)	-124	-148	-123	-129	-130	-106	-78	-43	-48	-41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-122	-143	-122	-129	-132	-110	-79	-45	-51	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.15	5.09	6.51	12.28	15.04	42.93	18.56	21.07	18.71	18.55
Price to Tangible Book Value (P/TBV)	6.15	5.09	6.51	12.28	15.04	42.93	18.56	21.07	18.71	18.55
Price to Revenue (P/Rev)	14.45	12.85	13.19	16.94	14.09	22.48	20.43	18.60	13.49	10.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	24.88	32.75	28.66	64.37	48.01	52.13	62.23	63.40
Enterprise Value to Revenue (EV/Rev)	12.06	10.27	11.63	16.05	13.63	22.31	19.74	18.07	12.98	10.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.85	1.07	1.55	2.04	3.59	5.54	1.74	2.10	2.11	2.17
Long-Term Debt to Equity	0.82	1.04	1.51	1.99	3.44	5.30	1.64	1.95	1.96	2.03
Financial Leverage	-1.03	-1.05	-0.94	-0.83	-0.89	-0.88	-0.71	-0.63	-0.63	-0.60
Leverage Ratio	1.56	1.75	1.82	2.17	3.04	3.72	3.12	3.66	4.47	5.19
Compound Leverage Factor	1.66	1.86	1.91	2.24	3.13	3.90	-3.55	4.24	5.17	6.21
Debt to Total Capital	45.82%	51.76%	60.80%	67.15%	78.21%	84.70%	63.52%	67.79%	67.81%	68.49%
Short-Term Debt to Total Capital	1.29%	1.58%	1.64%	1.89%	3.25%	3.55%	3.54%	4.85%	4.63%	4.63%
Long-Term Debt to Total Capital	44.53%	50.18%	59.16%	65.26%	74.97%	81.15%	59.98%	62.93%	63.19%	63.86%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.18%	48.24%	39.20%	32.85%	21.79%	15.30%	36.48%	32.21%	32.19%	31.51%
Debt to EBITDA	-0.78	-1.05	-1.19	-1.25	-1.38	-1.47	-1.20	-1.84	-2.32	-2.98
Net Debt to EBITDA	0.93	1.00	0.59	0.39	0.19	0.09	0.43	0.53	0.78	0.98
Long-Term Debt to EBITDA	-0.75	-1.02	-1.16	-1.22	-1.33	-1.41	-1.14	-1.71	-2.16	-2.77
Debt to NOPAT	-1.10	-1.47	-1.65	-1.73	-1.96	-2.12	-1.75	-2.70	-3.42	-4.37
Net Debt to NOPAT	1.32	1.40	0.82	0.54	0.27	0.13	0.63	0.78	1.15	1.45
Long-Term Debt to NOPAT	-1.07	-1.42	-1.61	-1.68	-1.88	-2.04	-1.66	-2.51	-3.18	-4.08
Altman Z-Score	2.05	0.54	0.31	0.75	-0.33	1.12	2.40	2.75	2.04	1.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.99	5.71	5.21	4.80	4.09	3.76	3.76	3.71	3.32	2.85
Quick Ratio	6.59	5.29	4.94	4.50	3.82	3.51	3.43	3.48	3.10	2.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-123	-157	-194	-130	-204	-172	-99	-45	-22	-26
Operating Cash Flow to CapEx	-3,483.24%	-8,197.50%	-4,758.55%	-5,108.65%	-1,671.46%	-1,689.02%	-9,195.02%	-1,871.23%	-54,548.00%	-3,150.64%
Free Cash Flow to Firm to Interest Expense	-14.64	0.00	-33.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-15.47	0.00	-21.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-15.91	0.00	-21.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.19	0.16	0.17	0.20	0.17	0.21	0.25	0.31	0.38	0.46
Accounts Receivable Turnover	14.44	8.38	6.81	6.67	7.14	7.52	6.18	5.88	8.11	8.58
Inventory Turnover	0.79	0.69	0.67	0.51	0.51	0.34	0.35	0.87	0.90	1.16
Fixed Asset Turnover	8.42	6.37	6.31	6.45	5.84	6.62	7.46	9.41	11.07	12.96
Accounts Payable Turnover	2.98	3.22	1.12	1.21	2.35	2.30	1.10	2.34	2.22	3.51
Days Sales Outstanding (DSO)	25.28	43.54	53.58	54.74	51.13	48.56	59.07	62.04	44.98	42.55
Days Inventory Outstanding (DIO)	461.04	527.78	546.80	717.50	718.85	1,088.16	1,033.68	419.82	407.66	315.29
Days Payable Outstanding (DPO)	122.61	113.33	327.21	301.28	155.64	158.97	330.38	156.25	164.26	104.09
Cash Conversion Cycle (CCC)	363.71	457.99	273.16	470.97	614.34	977.75	762.37	325.61	288.38	253.75
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-11	-12	96	111	103	86	116	126	91	84
Invested Capital Turnover	-9.47	-5.40	4.87	2.50	4.70	6.67	2.67	3.07	4.49	5.97
Increase / (Decrease) in Invested Capital	36	52	107	41	114	98	20	15	-12	-2.42
Enterprise Value (EV)	3,284	2,095	2,380	3,621	2,947	5,563	5,572	6,554	5,637	5,326
Market Capitalization	3,935	2,621	2,699	3,822	3,047	5,607	5,767	6,749	5,859	5,541
Book Value per Share	$10.72	$8.60	$6.91	$5.15	$3.34	$2.15	$5.05	$5.11	$4.94	$4.70
Tangible Book Value per Share	$10.72	$8.60	$6.91	$5.15	$3.34	$2.15	$5.05	$5.11	$4.94	$4.70
Total Capital	1,182	1,067	1,057	947	930	854	852	994	973	948
Total Debt	542	552	643	636	727	723	541	674	660	649
Total Long-Term Debt	526	535	625	618	697	693	511	626	615	605
Net Debt	-651	-526	-319	-201	-100	-44	-195	-195	-223	-215
Capital Expenditures (CapEx)	3.73	1.48	2.58	2.55	6.25	4.67	1.10	2.57	0.03	0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-70	-65	-77	-62	-72	-87	-48	-56	-92	-90
Debt-free Net Working Capital (DFNWC)	1,067	880	745	660	641	624	600	708	642	526
Net Working Capital (NWC)	1,052	863	728	642	611	593	570	660	597	482
Net Nonoperating Expense (NNE)	46	54	43	43	43	37	-168	20	22	21
Net Nonoperating Obligations (NNO)	-651	-526	-319	-201	-100	-44	-195	-195	-223	-215
Total Depreciation and Amortization (D&A)	1.62	5.19	1.30	-0.13	-2.57	-4.41	-0.38	-2.03	-2.47	-1.29
Debt-free, Cash-free Net Working Capital to Revenue	-25.53%	-31.72%	-37.69%	-27.69%	-33.29%	-34.84%	-16.91%	-15.33%	-21.17%	-17.63%
Debt-free Net Working Capital to Revenue	392.05%	431.43%	364.16%	292.61%	296.48%	250.12%	212.67%	195.15%	147.84%	103.34%
Net Working Capital to Revenue	386.43%	423.17%	355.66%	284.69%	282.51%	237.98%	201.98%	181.85%	137.47%	94.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.23)	($2.65)	($2.15)	($2.19)	($2.20)	($1.83)	$1.45	($0.80)	($0.89)	($0.83)
Adjusted Weighted Average Basic Shares Outstanding	59.76M	59.64M	60.13M	60.52M	60.69M	60.56M	61.58M	62.85M	63.38M	62.86M
Adjusted Diluted Earnings per Share	($2.23)	($2.65)	($2.15)	($2.19)	($2.20)	($1.83)	$1.40	($0.80)	($0.89)	($0.78)
Adjusted Weighted Average Diluted Shares Outstanding	59.76M	59.64M	60.13M	60.52M	60.69M	60.56M	63.80M	62.85M	63.38M	62.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.83M	59.98M	60.47M	60.66M	60.79M	61.23M	62.62M	63.35M	63.53M	63.91M
Normalized Net Operating Profit after Tax (NOPAT)	-87	-105	-87	-90	-90	-74	-79	-30	-34	-29
Normalized NOPAT Margin	-131.85%	-270.39%	-137.38%	-155.61%	-159.61%	-102.25%	-81.84%	-21.81%	-26.74%	-19.70%
Pre Tax Income Margin	-200.49%	-406.41%	-203.90%	-230.33%	-236.04%	-154.06%	92.93%	-36.11%	-43.69%	-33.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.75	0.00	-21.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-10.36	0.00	-14.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-15.20	0.00	-21.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-10.81	0.00	-15.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Blueprint Medicines' Financials

When does Blueprint Medicines's fiscal year end?

According to the most recent income statement we have on file, Blueprint Medicines' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Blueprint Medicines' net income changed over the last 9 years?

Blueprint Medicines' net income appears to be on an upward trend, with a most recent value of -$67.09 million in 2024, rising from -$52.77 million in 2015. The previous period was -$506.98 million in 2023.

What is Blueprint Medicines's operating income?

Blueprint Medicines's total operating income in 2024 was -$212.04 million, based on the following breakdown:

Total Gross Profit: $488.66 million
Total Operating Expenses: $700.71 million

How has Blueprint Medicines revenue changed over the last 9 years?

Over the last 9 years, Blueprint Medicines' total revenue changed from $11.40 million in 2015 to $508.82 million in 2024, a change of 4,363.4%.

How much debt does Blueprint Medicines have?

Blueprint Medicines' total liabilities were at $881.15 million at the end of 2024, a 4.1% decrease from 2023, and a 2,423.4% increase since 2015.

How much cash does Blueprint Medicines have?

In the past 9 years, Blueprint Medicines' cash and equivalents has ranged from $52.07 million in 2016 to $684.64 million in 2020, and is currently $102.01 million as of their latest financial filing in 2024.

How has Blueprint Medicines' book value per share changed over the last 9 years?

Over the last 9 years, Blueprint Medicines' book value per share changed from 5.31 in 2015 to 4.70 in 2024, a change of -11.5%.

Remove Ads

Related Companies

This page (NASDAQ:BPMC) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blueprint Medicines (BPMC) Financials

Frequently Asked Questions About Blueprint Medicines' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Blueprint Medicines (BPMC) Financials

Annual Income Statements for Blueprint Medicines

Quarterly Income Statements for Blueprint Medicines

Annual Cash Flow Statements for Blueprint Medicines

Quarterly Cash Flow Statements for Blueprint Medicines

Annual Balance Sheets for Blueprint Medicines

Quarterly Balance Sheets for Blueprint Medicines

Annual Metrics and Ratios for Blueprint Medicines

Quarterly Metrics and Ratios for Blueprint Medicines

Frequently Asked Questions About Blueprint Medicines' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools